Introduction
============

Chronic obstructive pulmonary disease (COPD) is currently the fifth leading cause of death worldwide, and is projected to be the fourth by 2030.[@b1-copd-11-455] COPD affects 10%--20% of adults aged 40 years and older[@b2-copd-11-455]--[@b4-copd-11-455] and is one of the leading causes of hospitalization and high health care costs.[@b5-copd-11-455]--[@b7-copd-11-455] Acute exacerbations are responsible for up to 60% of the costs attributable to COPD,[@b5-copd-11-455],[@b8-copd-11-455] and they reduce quality of life[@b9-copd-11-455] and speed disease progression.[@b10-copd-11-455]

Previous studies have shown that 50%--75% of exacerbations are associated with respiratory infections,[@b11-copd-11-455] with an unknown proportion associated with pneumonia. Patients with COPD are at greater risk of developing pneumonia than the general population,[@b12-copd-11-455]--[@b14-copd-11-455] and COPD is an adverse prognostic factor for patients hospitalized with pneumonia.[@b15-copd-11-455] However, little is known about the rate of COPD exacerbations with and without pneumonia, or about the impact of pneumonia on severity and outcomes of COPD exacerbations. The few previous studies reached conflicting conclusions, showing either no difference in 30-day mortality among patients with nonpneumonic and pneumonic COPD exacerbations[@b16-copd-11-455],[@b17-copd-11-455] or up to 14% increased in-hospital mortality among patients with pneumonic exacerbations.[@b18-copd-11-455],[@b19-copd-11-455] Pneumonia may worsen the course of COPD exacerbations due to thickening of the blood--gas barrier, leading to pulmonary dysfunction and increased hypoxemia, systemic inflammation, and risk of severe sepsis with hypotension and decreased perfusion of vital organs. Little is known about how pneumonic versus nonpneumonic exacerbations predict the risk of subsequent COPD exacerbations.[@b10-copd-11-455]

The aim of our study was to examine incidence, health resource utilization, 30-day mortality, and risk of new hospitalizations for COPD exacerbation among patients with successive COPD exacerbations with and without pneumonia in Denmark during 2006--2012.

Material and methods
====================

Setting
-------

Denmark provides its entire population (5.6 million persons) with tax-supported health care and partial reimbursement for prescribed medications. A unique central personal registration number, assigned to all Danish residents at birth or upon immigration, is used to record health care services in various nationwide registries, allowing unambiguous linkage among registries.[@b20-copd-11-455] The current nationwide cohort study is based on information from these registries.

Data sources
------------

The Danish National Patient Registry (DNPR) provides information on all inpatient admissions to hospitals since 1977, and on all outpatient and emergency room visits since 1995.[@b21-copd-11-455] For each hospitalization, DNPR files contain data on dates of admission and discharge, surgical procedures performed, if any, and up to 20 discharge diagnoses coded according to the International Classification of Diseases (ICD).

Information on all prescription drugs is maintained in the Danish National Health Service Prescription.[@b22-copd-11-455] This database records patients' personal identifier, date of dispensing, and type and quantity of drug prescribed (according to the Anatomical Therapeutic Chemical classification system) each time a prescription is redeemed at any Danish pharmacy.

The Danish Civil Registration System (CRS) records information on date of birth, sex, change of address, date of immigration or emigration, and changes in vital status, with daily updates for all individuals legally residing in Denmark at any time since 1968.[@b20-copd-11-455] The CRS allows for complete follow-up of all residents of Denmark.

All ICD and Anatomical Therapeutic Chemical codes used in this study are provided in the [Table S1](#SD1-copd-11-455){ref-type="supplementary-material"}.

Identification of patients hospitalized for a COPD exacerbation with and without pneumonia
------------------------------------------------------------------------------------------

We used the DNPR to identify all first-time acute inpatient hospitalizations for COPD exacerbations in Denmark between 2006 and 2012.[@b6-copd-11-455],[@b23-copd-11-455] COPD exacerbation was defined as acute admission with either a primary COPD discharge diagnosis or a primary diagnosis of respiratory tract infection, bronchitis, asthma, acute respiratory distress syndrome, or respiratory failure, combined with a secondary diagnosis of COPD listed during the same admission, or a previous primary diagnosis of COPD present within the preceding 10 years.[@b10-copd-11-455] We used this expanded definition of COPD exacerbations because restriction to only hospitalizations coded with primary COPD discharge diagnoses results in a documented underreporting of hospitalized COPD exacerbations.[@b23-copd-11-455] We excluded patients younger than age 40 years at the time of their first COPD hospitalization, given the low COPD prevalence in young people[@b6-copd-11-455] and the potential risk of misclassification of asthma as COPD.

We categorized all COPD hospitalizations according to whether or not they included a primary or secondary diagnosis of pneumonia.

Data on confounding factors
---------------------------

We computed Charlson Comorbidity Index (CCI) scores for each patient based on all hospital diagnoses in DNPR records within 10 years preceding the date of the first hospitalization for COPD.[@b24-copd-11-455] We categorized severity of comorbidity as none (CCI score =0), medium (CCI score =1−2), or high (CCI score ≥3).[@b25-copd-11-455] Because alcoholism-related diseases, atrial fibrillation/flutter, asthma, hypertension, osteoporosis, depression, and venous thromboembolism may affect the prognosis of COPD patients and are not included in the CCI, we also identified previous hospitalizations for these conditions. As a marker of social support, we obtained information on marital status (married, never married, divorced, widowed, or unknown) from the CRS.[@b26-copd-11-455] To assess the impact of COPD severity, we categorized patients according to their current use of short- and long-acting β-agonists, inhaled corticosteroids (beclomethasone, mometasone, fluticasone, and budesonide), combinations of inhaled corticosteroids and long-acting β-agonists, and intermittent or continuous use of systemic corticosteroids ([Table S1](#SD1-copd-11-455){ref-type="supplementary-material"}).

Health resource utilization, 30-day mortality, and new exacerbations
--------------------------------------------------------------------

We estimated health resource utilization associated with each exacerbation by length of stay (defined as the difference between admission and discharge dates), admission to an intensive care unit, use of mechanical and noninvasive ventilation, inotropics and dialysis, and all-cause 30-day acute readmissions (defined as any readmission within 30 days following the index discharge). Information on these health resource utilization measures was obtained from the DNRP. Up-to-date information on mortality within 30 days of exacerbation was obtained from the CRS.[@b20-copd-11-455] Data on new hospitalizations for COPD exacerbations were obtained from the DNRP.

Statistical analysis
--------------------

We compared patient characteristics and associated health resource utilization among patients hospitalized for a COPD exacerbation, with and without pneumonia. Descriptive statistics were produced using frequencies, proportions, and prevalence proportion ratios (PPRs) for categorical data, and means, medians, and interquartile ranges (IQR) for continuous variables. We then computed overall rates of first COPD exacerbations, with and without pneumonia, as the number of first exacerbations per year divided by the corresponding midyear population above 40 years in Denmark (obtained from Statistics Denmark).

To examine the risk of 30-day mortality and of a new exacerbation, we followed patients from the date of their first hospitalization for a COPD exacerbation until death from any cause, emigration, or December 31, 2012, whichever came first. To assess the effect of each successive exacerbation on the risk of 30-day mortality, we used Cox regression analysis to compute the hazard ratio (HR) of 30-day mortality comparing COPD patients with and without pneumonic exacerbations. Thus, we assessed the risk of death from the admission date with first exacerbation among all patients with a first exacerbation, from the admission date with second exacerbation among all patients with a second exacerbation, and so forth. Age at first exacerbation, sex, CCI score, and respiratory medications as a marker of COPD severity were included as adjustment factors for the effect of pneumonia. The same Cox regression analysis approach was used to assess the effect of each successive COPD exacerbation on the risk of another hospitalization for an exacerbation during follow-up, considering death a competing risk.[@b27-copd-11-455] To increase the likelihood of a correct diagnosis of COPD, we conducted a sensitivity analysis in which we excluded all patients with only a diagnosis of simple and mucopurulent chronic bronchitis or chronic bronchitis. Furthermore, because patients with pneumonic COPD exacerbations might be coded as having "COPD with acute lower respiratory infection" rather than pneumonia, we also conducted a sensitivity analysis in which we categorized these patients as having a pneumonic exacerbation.

All statistical analyses were conducted using SAS 9.2 (SAS Institute Inc., Cary, NC, USA). The study was approved by the Danish Data Protection Agency (record no 2012-41-0793). According to Danish law, use of registry data for research purposes does not require informed consent.

Results
=======

Hospitalization rates for COPD exacerbations with and without pneumonia
-----------------------------------------------------------------------

We identified 179,759 hospitalizations for COPD exacerbations in Denmark during 2006--2012. Of these, 119,877 (66.7%) were nonpneumonic and 59,882 (33.3%) were pneumonic. Among the 52,520 patients with a first-time hospitalization for a COPD exacerbation, 33,552 (63.9%) had a nonpneumonic exacerbation and 18,968 (36.1%) had a pneumonic exacerbation. The proportion of patients with pneumonic exacerbations decreased with an increasing number of exacerbations, reaching 25.6% for seven or more exacerbations ([Figure 1](#f1-copd-11-455){ref-type="fig"}). The annual rate of hospitalizations for nonpneumonic exacerbations decreased by 6% from 1.74 per 1,000 population aged 40 years or older in 2006 to 1.63 per 1,000 population aged 40 years or older in 2012. Concurrently, rates of pneumonic COPD exacerbations increased by 20%, reaching 1.10 per 1,000 population aged 40 years or older in 2012 ([Figure 2](#f2-copd-11-455){ref-type="fig"}).

Patient characteristics and health resource utilization
-------------------------------------------------------

Characteristics of patients with a first-time hospitalization for a COPD exacerbation are listed in [Table 1](#t1-copd-11-455){ref-type="table"}. Patients with a pneumonic exacerbation had a slightly lower probability than patients with a nonpneumonic exacerbation of receiving any respiratory medication within the 365 days preceding the index admission (72.0% vs 76.5%). As well, patients with nonpneumonic exacerbations were more likely than patients with pneumonic exacerbations to use oral corticosteroids (26.8% vs 20.7%). Patients with a first-time pneumonic exacerbation were slightly older (median age 75 years, IQR 66--82 years) than patients with a nonpneumonic exacerbation (median age 73 years, IQR 64--80 years), and had a higher prevalence of virtually all comorbidities included in the analysis (57.4% had a CCI score ≥1 compared with 50.7% of patients with nonpneumonic exacerbations) ([Figure 3](#f3-copd-11-455){ref-type="fig"}).

[Table 2](#t2-copd-11-455){ref-type="table"} shows the health resource utilization associated with first-time COPD exacerbations. The median length of hospital stay was 4 days (IQR 2--8 days) for patients with a nonpneumonic exacerbation and 7 days (IQR 4--11 days) for patients with a pneumonic exacerbation. Mechanical or noninvasive ventilation was provided to 3.3% and 6.7% of patients with nonpneumonic exacerbations respectively, compared with 6.9% and 9.7% of patients with pneumonic exacerbations. Patients with pneumonic exacerbations were also more likely to receive inotropic therapy (PPR 2.15, 95% confidence interval \[CI\] 1.94--2.37) or dialysis (PPR 1.74, 95% CI 1.39--2.17), and were slightly more likely to be readmitted for any cause within 30 days following discharge (PPR 1.04, 95% CI 1.00--1.08) compared with patients with nonpneumonic exacerbations ([Table 2](#t2-copd-11-455){ref-type="table"}).

Thirty-day mortality
--------------------

Thirty-day mortality was 12.1% in patients with a first-time pneumonic exacerbation and 8.4% in those with a first-time nonpneumonic exacerbation, equivalent to an adjusted HR (aHR) of 1.21 (95% CI 1.17--1.24) after adjusting for age, sex, comorbidity, and respiratory medications ([Table 3](#t3-copd-11-455){ref-type="table"}). Presence of pneumonia also predicted increased mortality among patients hospitalized with a second exacerbation (aHR 1.14, 95% CI 1.11--1.18), and up to the seventh and subsequent exacerbation (aHR 1.10, 95% CI 1.07--1.13).

Among patients with a pneumonic COPD exacerbation, 37.3% had at least one subsequent severe exacerbation requiring hospitalization during median follow-up of 203 days, compared with 43.4% of patients with a nonpneumonic exacerbation during median follow-up of 213 days ([Table 4](#t4-copd-11-455){ref-type="table"}). After taking into account death as a competing risk, the corresponding aHR of a subsequent hospitalization for an exacerbation associated with pneumonia was 0.93 (95% CI 0.91--0.96). The time span between successive exacerbations diminished with increasing number of exacerbations, both for pneumonic and nonpneumonic exacerbations. Nonetheless, the aHR of a subsequent exacerbation was 8%--13% lower for patients with pneumonic versus nonpneumonic exacerbations across numbers of exacerbations.

In the sensitivity analysis excluding patients with bronchitis, presence of pneumonia remained consistently associated with increased risk of death and lower risk of a subsequent exacerbation across numbers of exacerbations (data not shown). At their first-time hospitalization for a COPD exacerbation, 9.5% of patients had a diagnosis of "COPD with acute lower respiratory infection." Categorizing these patients as having pneumonic exacerbations attenuated the difference between pneumonic and nonpneumonic COPD exacerbations ([Table S2](#SD2-copd-11-455){ref-type="supplementary-material"}).

Discussion
==========

This nationwide population-based cohort study showed a large and apparently increasing burden of pneumonic COPD exacerbations. Approximately 36% of patients hospitalized for a first-time exacerbation also received a pneumonia diagnosis. During 2006--2012, the incidence of first-time hospitalizations for pneumonic exacerbations increased by 20%. Over the same period, the rate of nonpneumonic exacerbations decreased by 6%. Patients with pneumonic exacerbations were older, had more comorbidity, and required more health resources in terms of a prolonged hospital stay, increased use of intensive care, assisted ventilation, inotropic therapy, dialysis, and readmission. Pneumonic exacerbations were also associated with higher 30-day mortality compared with nonpneumonic exacerbations, both in first-time and successive exacerbations, and after adjustment for age, sex, comorbidity, and COPD severity. At the same time, patients with nonpneumonic COPD exacerbations had a slightly higher risk of subsequent hospitalizations for exacerbations than patients with pneumonic exacerbations, regardless of number of exacerbations.

The paucity of data on pneumonic versus nonpneumonic exacerbations to some extent may stem from controversy as to whether or not a case of manifest pneumonia should be considered as part of a COPD exacerbation. Some consider pneumonia and acute exacerbations in COPD patients as separate acute events.[@b16-copd-11-455],[@b28-copd-11-455] Still, the British Thoracic Society includes COPD patients with X-ray-confirmed pneumonia in their national audit of COPD exacerbations.[@b19-copd-11-455] The Global Initiative for Chronic Obstructive Lung Disease defines an exacerbation as an event in the clinical course of COPD characterized by amplification of the state of chronic inflammation in the airways and acute onset of aggravation of baseline symptoms beyond normal day-to-day variations and leading to a change in medication.[@b29-copd-11-455] This broad definition may include a wide range of manifestations, including those of pneumonia.[@b30-copd-11-455] Accordingly, in this study, we considered hospitalization for pneumonia to be a COPD exacerbation.

Compared with the few previous studies,[@b17-copd-11-455]--[@b19-copd-11-455],[@b31-copd-11-455] we identified a relatively high proportion of patients with a first-time pneumonic COPD exacerbation. In a recent Norwegian study of 1,144 patients hospitalized with COPD exacerbations, 237 (20.7%) had pneumonia defined as a pneumonic infiltrate on X-ray and CRP equal to or above 40 mg/L.[@b17-copd-11-455] In the 2008 National UK COPD audit, 16% of patients hospitalized with a COPD exacerbation presented with radiographic consolidation.[@b19-copd-11-455] In another study, 23 (9%) patients among 250 patients hospitalized for acute exacerbation had X-ray findings indicating pneumonia.[@b31-copd-11-455] In contrast with our study, these studies focused on prevalent rather than incident episodes. We showed that the proportion of pneumonic exacerbations declined with the number of exacerbations, which explains part of the differences in findings. In their study, Steer et al[@b18-copd-11-455] included patients with a first-time hospitalization for a COPD exacerbation and found that 299 (33%) of 920 patients were categorized with pneumonic exacerbations based on X-ray findings. This is in line with our finding that 36% of patients in our study who presented with a first-time COPD exacerbation had pneumonia. Also corroborating our findings, earlier studies reported that patients with pneumonic exacerbations tend to be older, have more comorbidity, a longer length of stay, and more assisted ventilation compared with patients with nonpneumonic exacerbations.[@b17-copd-11-455]--[@b19-copd-11-455]

In line with the findings of Suissa et al,[@b10-copd-11-455] we observed that severe exacerbations appeared to recur progressively sooner after each subsequent severe exacerbation. The reason for the apparently higher risk of subsequent exacerbations among those with nonpneumonic exacerbations is not clear, but might be related to a phenotype associated with persistent and increased propensity for airway and systemic inflammation[@b32-copd-11-455] without a propensity for manifest respiratory tract infection. Another explanation may be more intensive antibiotic therapy given to patients with manifest pneumonia, including possible prophylactic use of azithromycin in some patients, which may prevent or delay new COPD exacerbations.[@b33-copd-11-455],[@b34-copd-11-455] Use of inhaled corticosteroids has been associated with decreased risk of subsequent exacerbations and increased risk for hospitalization with pneumonia.[@b35-copd-11-455] However, prior use of inhaled corticosteroids differed little among nonpneumonic and pneumonic first-time admitted patients in our study, and therefore also was unlikely to explain any observed differences in mortality.[@b36-copd-11-455] To some extent, the higher risk of subsequent exacerbation in patients following nonpneumonic exacerbations may have been related to the higher mortality during index admission in those with pneumonic exacerbation, leaving fewer frail patients at risk of subsequent exacerbations (depletion of susceptibles).

Our estimates of COPD exacerbation and mortality are based on a nationwide cohort study conducted in a setting in which a national health service provides unfettered access to health care, thus largely eliminating referral and diagnostic biases. Our study included the entire Danish population and had complete follow-up through the use of nationwide registries, so it also avoided the selection biases hampering clinic-based studies.

Our study also has limitations. It is important to note that our results focused only on COPD exacerbations requiring hospitalization. As well, the accuracy of diagnoses of pneumonic and nonpneumonic COPD exacerbation were dependent on proper ICD-10 coding. Previous DNRP validation studies have revealed positive predictive value 92%--100% of ICD codes for primary COPD[@b25-copd-11-455] and COPD exacerbations.[@b23-copd-11-455] Our data had similarly high accuracy for detecting pneumonia requiring hospitalization (ie, a predictive value of \~90%)[@b37-copd-11-455],[@b38-copd-11-455] and for the comorbid conditions in the CCI.[@b25-copd-11-455] The validity of pneumonia codes associated with COPD has not been well studied. The decline in the proportion of exacerbations with pneumonia over subsequent episodes may suggest that the likelihood of actually having COPD increases with each episode. However, any misclassification between pneumonic and nonpneumonic episodes would tend to diminish observed differences between the two conditions, not changing our conclusions. Another limitation is the lack of clinical data on the length of each exacerbation, making it difficult to differentiate between relapse and recurrence.[@b10-copd-11-455],[@b39-copd-11-455],[@b40-copd-11-455] However, the majority of patients recover within 30 days after the onset of a COPD exacerbation.[@b40-copd-11-455] In our data, the median time between hospitalizations ranged from 38 to 213 days, supporting the conclusion that they are in fact recurrent events. We also lacked clinical data on severity of symptoms, airflow limitations, and exercise intolerance, and lifestyle factors such as poor nutrition, alcohol consumption, and tobacco smoking that may influence prognosis.[@b41-copd-11-455] However, we were able to control for hospital diagnoses of alcohol-related conditions and many other lifestyle-related diseases including diabetes, cardiovascular disease, and cancer.

We conclude that pneumonia is common in patients hospitalized with acute COPD exacerbations and is associated with increased health resource utilization and poor prognosis compared with patients with nonpneumonic exacerbations. Our results emphasize the need for increased attention to treatment and prevention of pneumonia in patients with COPD.

Supplementary materials
=======================

###### 

ICD and ATC classification system codes used in the study

  ------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Codes used for identifying COPD exacerbation**                         
  Simple and mucopurulent chronic bronchitis                               ICD-10: J41
  Chronic bronchitis                                                       ICD-10: J42
  Emphysema                                                                ICD-10: J43
  COPD                                                                     ICD-10: J44
  Respiratory failure                                                      ICD-10: J96
  Acute respiratory infection                                              ICD-10: J00--J06, J09--J11, J13, J14--J18, J20--J22
  Chronic lower respiratory disease                                        ICD-10: J40--J47
  Acute respiratory distress                                               ICD-10: J80
  Abscess of lung or pyothorax/empyema                                     ICD-10: J85--J86
  **Codes used for identifying pneumonia**                                 ICD-10: J12--J18
  **Charlson Comorbidity Index**                                           
  Score 1                                                                  
   Myocardial infarction                                                   ICD-10: I21, I22, I23
   Congestive heart failure                                                ICD-10: I50, I11.0, I13.0, I13.2
   Peripheral vascular disease                                             ICD-10: I70, I71, I72, I73, I74, I77
   Cerebrovascular disease                                                 ICD-10: I60--I69, G45, G46
   Dementia                                                                ICD-10: F00--F03, F05.1, G30
   Chronic pulmonary disease[\*](#tfn9-copd-11-455){ref-type="table-fn"}   ICD-10: J40, J45--J47, J60--J67, J68.4, J70.1, J70.3, J84.1, J92.0, J96.1, J98.2, J98.3
   Connective tissue disease                                               ICD-10: M05, M06, M08, M09, M30, M31, M32, M33, M34, M35, M36, D86
   Ulcer disease                                                           ICD-10: K22.1, K25--K28
   Mild liver disease                                                      ICD-10: B18, K70.0--K70.3, K70.9, K71, K73, K74, K76.0
   Diabetes types 1 and 2                                                  ICD-10: E10.0, E10.1, E10.9, E11.0, E11.1, E11.9
  Score 2                                                                  
   Hemiplegia                                                              ICD-10: G81, G82
   Moderate-to-severe renal disease                                        ICD-10: 12, I13, N00--N05, N07, N11, N14, N17--N19, Q61
   Diabetes with end-organ damage                                          ICD-10: E10.2--E10.8, E11.2--E11.8
   Any tumor                                                               ICD-10: C00--C75
   Leukemia                                                                ICD-10: C91--C95
   Lymphoma                                                                ICD-10: C81--C85, C88, C90, C96
  Score 3                                                                  
   Moderate-to-severe liver disease                                        ICD-10: B15.0, B16.0, B16.2, B19.0, K70.4, K72, K76.6, I85
  Score 6                                                                  
   Metastatic solid tumor                                                  ICD-10: C76--C80
   AIDS                                                                    ICD-10: B21--B24
  **Additional comorbidities**                                             
  Alcoholism-related diseases                                              ICD-10: F10.7--F10.9, G31.2, G62.1, G72.1, I42.6, K.29.2, K70, K86.0
  Atrial fibrillation/flutter                                              ICD-10: I48
  Asthma                                                                   ICD-10: J45
  Hypertension                                                             ICD-10: I10--I13
  Osteoporosis                                                             ICD-10: M80, M81
  Venous thromboembolism                                                   ICD-10: I80.1--3; I26.0; I26.9
  **Additional codes**                                                     
  Mechanical ventilation                                                   Treatment code: BGDA0
  Noninvasive mechanical ventilation                                       Treatment code: BGDA1
  Dialysis                                                                 ICD-10: BJFD0
  Treatment with inotropic agents                                          Treatment code: BFHC92; BFHC93; BFHC95
  **Respiratory medications**                                              
  1\) COPD with continuous oral glucocorticoid treatment                   ≥1 prescription for medications with ATC code H02AB group (except injections) 365 days before index date, with medication possession ratio \>0.7, ie, total number of pills in package(s) covering more than 70% of the 365 days
  2\) COPD with oral glucocorticoid treatment                              ≥1 prescription for medications with ATC code H02AB group (except injections) 365 days before index date
  3\) COPD with inhaled corticosteroid treatment                           ≥1 prescription 365 days before index date of inhaled corticosteroids: beclomethasone, mometasone, fluticasone, budesonide (ATC codes R03BA01, R03BA02, R03BA03, R03BA05, R03BA07), or combinations of inhaled corticosteroids and long acting β-agonists: salmeterol + fluticasone and formoterol + budesonide (ATC codes R03AK06 and R03AK07, respectively)
  4\) COPD treated with other therapies than corticosteroids               ≥1 prescriptions for medications with ATC code R03 group other than those in group 3 within 365 days before index date
  ------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

Excluding COPD ICD-10: J41--J44.

**Abbreviations:** ATC, Anatomical Therapeutic Chemical; COPD, chronic obstructive pulmonary disease; ICD, International classification of diseases.

###### 

Sensitivity analysis categorizing patients with a discharge diagnosis of "chronic obstructive pulmonary disease with acute lower respiratory infection" (ICD-10: J44.0) as having a pneumonic COPD exacerbation

  Exacerbation number   Exacerbation type   Risk of 30-day mortality   Risk of a subsequent hospitalization for a COPD exacerbation                                              
  --------------------- ------------------- -------------------------- -------------------------------------------------------------- --------------- ------ ------------------- ---------------
  First                 Nonpneumonic        28,582 (54.4)              8.4                                                            1 (reference)   209    42.8                1 (reference)
  Pneumonic             23,938 (45.6)       11.3                       1.15 (1.11--1.18)                                              214             39.2   0.97 (0.94--1.00)   
  Second                Nonpneumonic        15,928 (52.0)              10.5                                                           1 (reference)   141    57.9                1 (reference)
  Pneumonic             14,724 (48.0)       13.7                       1.10 (1.07--1.14)                                              146             51.0   0.91 (0.88--0.94)   
  Third                 Nonpneumonic        11,046 (53.8)              10.6                                                           1 (reference)   105    65.0                1 (reference)
  Pneumonic             9,483 (46.2)        14.0                       1.12 (1.08--1.16)                                              117             58.4   0.94 (0.91--0.97)   
  Fourth                Nonpneumonic        8,164 (55.8)               10.8                                                           1 (reference)   82     70.0                1 (reference)
  Pneumonic             6,470 (44.2)        12.3                       1.07 (1.02--1.11)                                              94              64.0   0.90 (0.87--0.94)   
  Fifth                 Nonpneumonic        6,308 (57.5)               10.7                                                           1 (reference)   74     72.1                1 (reference)
  Pneumonic             4,666 (42.5)        12.8                       1.10 (1.04--1.15)                                              84              66.7   0.92 (0.88--0.97)   
  Sixth                 Nonpneumonic        4,923 (58.4)               10.2                                                           1 (reference)   63     75.2                1 (reference)
  Pneumonic             3,503 (41.6)        12.4                       1.11 (1.05--1.18)                                              74              69.7   0.92 (0.88--0.97)   
  Seventh or greater    Nonpneumonic        26,414 (62.9)              8.7                                                            1 (reference)   38     82.8                1 (reference)
  Pneumonic             15,610 (31.7)       10.8                       1.09 (0.07--1.12)                                              45              77.6   0.91 (0.89--0.93)   

**Note:**

Adjusted for age, sex, CCI score, and respiratory medications as a marker of COPD severity.

**Abbreviations:** CI, confidence interval; CCI, Charlson Comorbidity Index; COPD, chronic obstructive pulmonary disease; HR, hazard ratio.

This study was partly supported by a research grant from Pfizer A/S to Aarhus University.
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###### 

Baseline characteristics of patients with a first-time hospitalization for a COPD exacerbation in Denmark, 2006--2012

  Characteristic                                                       Exacerbation type                   
  -------------------------------------------------------------------- ------------------- ------ -------- ------
  Overall                                                              33,552              100    18,968   100
  Respiratory medications in the year prior to first hospitalization                                       
   No respiratory medication use                                       7,897               23.5   5,309    28.0
   Use of respiratory medications other than inhaled corticosteroids   11,030              32.9   6,592    34.8
   Use of inhaled corticosteroids                                      3,388               10.1   1,788    9.4
   Use of oral corticosteroids                                         8,979               26.8   3,917    20.7
   Continuous use of oral corticosteroids                              2,258               6.7    1,362    7.2
  Sex                                                                                                      
   Female                                                              18,400              54.8   9,411    49.6
   Male                                                                15,152              45.2   9,557    50.4
  Age, years                                                                                               
   40--49                                                              1,538               4.6    552      2.9
   50--59                                                              4,036               12.0   1,792    9.4
   60--69                                                              7,954               23.7   4,125    21.7
   70--79                                                              11,247              33.5   6,421    33.9
   80--89                                                              7,789               23.2   5,291    27.9
   90 and older                                                        988                 2.9    787      4.1
  Marital status                                                                                           
   Married                                                             13,281              42.3   7,336    42.6
   Widowed                                                             9,841               29.3   5,765    30.4
   Divorced                                                            6,472               19.3   3,338    17.6
   Unmarried                                                           1,779               5.3    857      4.5
   Unknown                                                             1,143               3.4    794      4.2
  CCI score                                                                                                
   0                                                                   16,527              49.3   8,083    42.6
   1                                                                   6,811               20.3   4,077    21.5
   2                                                                   5,067               15.1   3,146    16.6
   ≥3                                                                  5,147               15.3   3,662    19.3

**Abbreviations:** CCI, Charlson Comorbidity Index; COPD, chronic obstructive pulmonary disease.

###### 

Health resource utilization among patients with a first-time nonpneumonic or pneumonic COPD exacerbation, Denmark 2006--2012

  Health resource utilization             Exacerbation type   Prevalence proportion ratio pneumonic vs nonpneumonic (95% CI)   
  --------------------------------------- ------------------- ---------------------------------------------------------------- -------------------
  Median LOS (IQR), days                  4 (2--8)            7 (4--11)                                                        --
  ICU stay                                                                                                                     
   N (%)                                  2,585 (7.7)         2,373 (12.5)                                                     1.63 (1.54--1.71)
  Mechanical ventilation                                                                                                       
   N (%)                                  1,106 (3.3)         1,315 (6.9)                                                      2.10 (1.95--2.27)
  Noninvasive mechanical ventilation                                                                                           
   N (%)                                  2,240 (6.7)         1,841 (9.7)                                                      1.45 (1.37--1.54)
  Inotropic use                                                                                                                
   N (%)                                  756 (2.3)           920 (4.9)                                                        2.15 (1.94--2.37)
  Dialysis                                                                                                                     
   N (%)                                  157 (0.5)           154 (0.8)                                                        1.74 (1.39--2.17)
  30-day acute readmission of any cause                                                                                        
   N (%)                                  5,886 (17.5)        3,453 (18.2)                                                     1.04 (1.00--1.08)

**Abbreviations:** CI, confidence interval; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; IQR, interquartile range; LOS, length of stay.

###### 

Crude and adjusted risk of 30-day mortality according to number of exacerbation[a](#tfn3-copd-11-455){ref-type="table-fn"}

  Exacerbation number   Exacerbation type   Patients, N   30-day mortality (%)   Crude HR (95% CI)   Adjusted HR[b](#tfn4-copd-11-455){ref-type="table-fn"} (95% CI)
  --------------------- ------------------- ------------- ---------------------- ------------------- -----------------------------------------------------------------
  First                 Nonpneumonic        33,552        8.3                    1 (reference)       1 (reference)
  Pneumonic             18,968              12.1          1.35 (1.31--1.39)      1.20 (1.17--1.24)   
  Second                Nonpneumonic        18,774        10.2                   1 (reference)       1 (reference)
  Pneumonic             11,878              15.0          1.33 (1.29--1.38)      1.14 (1.11--1.18)   
  Third                 Nonpneumonic        13,173        10.4                   1 (reference)       1 (reference)
  Pneumonic             7,356               15.2          1.27 (1.22--1.32)      1.12 (1.08--1.17)   
  Fourth                Nonpneumonic        9,727         10.5                   1 (reference)       1 (reference)
  Pneumonic             4,907               13.5          1.20 (1.15--1.26)      1.08 (1.03--1.14)   
  Fifth                 Nonpneumonic        7,524         10.4                   1 (reference)       1 (reference)
  Pneumonic             3,450               14.1          1.22 (1.16--1.29)      1.10 (1.04--1.16)   
  Sixth                 Nonpneumonic        5,873         10.1                   1 (reference)       1 (reference)
  Pneumonic             2,553               13.3          1.19 (1.12--1.27)      1.12 (1.06--1.19)   
  Seventh or greater    Nonpneumonic        31,254        8.9                    1 (reference)       1 (reference)
  Pneumonic             10,770              11.3          1.17 (1.13--1.20)      1.10 (1.07--1.13)   

**Notes:**

Risk of death is assessed from the admission date with first exacerbation among all patients with a first exacerbation, from the admission date with second exacerbation among all patients who have a second exacerbation, and so forth.

Adjusted for age, sex, CCI score, and respiratory medications as a marker of COPD severity.

**Abbreviations:** CCI, Charlson Comorbidity Index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; HR, hazard ratio.

###### 

Crude and adjusted risk of a subsequent exacerbation according to number of exacerbation[a](#tfn6-copd-11-455){ref-type="table-fn"}

  Exacerbation number   Exacerbation type   Patients with exacerbation, N   Proportion with a subsequent exacerbation (%)   Median time to subsequent exacerbation (days)   Crude HR (95% CI)   Adjusted HR[b](#tfn7-copd-11-455){ref-type="table-fn"} (95% CI)
  --------------------- ------------------- ------------------------------- ----------------------------------------------- ----------------------------------------------- ------------------- -----------------------------------------------------------------
  First                 Pneumonic           14,560                          43.4                                            213                                             1 (reference)       1 (reference)
  Nonpneumonic          7,073               37.3                            206                                             0.94 (0.92--0.97)                               0.93 (0.91--0.96)   
  Second                Pneumonic           10,949                          58.3                                            142                                             1 (reference)       1 (reference)
  Nonpneumonic          5,786               48.7                            146                                             0.87 (0.85--0.90)                               0.88 (0.85--0.91)   
  Third                 Pneumonic           8,581                           65.1                                            106                                             1 (reference)       1 (reference)
  Nonpneumonic          4,131               56.2                            120                                             0.90 (0.86--0.93)                               0.92 (0.88--0.95)   
  Fourth                Pneumonic           6,838                           70.3                                            83                                              1 (reference)       1 (reference)
  Nonpneumonic          3,016               61.5                            97                                              0.86 (0.82--0.90)                               0.87 (0.84--0.91)   
  Fifth                 Pneumonic           5,433                           72.2                                            75                                              1 (reference)       1 (reference)
  Nonpneumonic          2,223               64.4                            86                                              0.90 (0.85--0.94)                               0.91 (0.86--0.95)   
  Sixth                 Pneumonic           4,405                           75.0                                            66                                              1 (reference)       1 (reference)
  Nonpneumonic          1,739               68.1                            74                                              0.93 (0.88--0.98)                               0.94 (0.89--1.00)   
  Seventh or greater    Pneumonic           25,839                          82.7                                            38                                              1 (reference)       1 (reference)
  Nonpneumonic          8,151               75.7                            48                                              0.86 (0.84--0.89)                               0.88 (0.86--0.90)   

**Notes:**

Risk of new exacerbation is assessed from the admission date with first exacerbation among all patients with a first exacerbation, from the admission date with second exacerbation among all patients who have a second exacerbation, and so forth.

Adjusted for age, sex, CCI score, and respiratory medications as a marker of COPD severity.

**Abbreviations:** CCI, Charlson Comorbidity Index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; HR, hazard ratio.
